Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.
about
Drug treatment for spinal muscular atrophy types II and IIIDrug treatment for spinal muscular atrophy type IDrug treatment for spinal muscular atrophy types II and IIIDrug treatment for spinal muscular atrophy type IDrug treatment for spinal muscular atrophy type IDrug treatment for spinal muscular atrophy types II and IIIA neuronal two P domain K+ channel stimulated by arachidonic acid and polyunsaturated fatty acids.Therapeutic neuroprotective agents for amyotrophic lateral sclerosisThe persistent sodium current blocker riluzole is antiarrhythmic and anti-ischaemic in a pig model of acute myocardial infarctionNovel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms.A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current.Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survivalRiluzole But Not Melatonin Ameliorates Acute Motor Neuron Degeneration and Moderately Inhibits SOD1-Mediated Excitotoxicity Induced Disrupted Mitochondrial Ca2+ Signaling in Amyotrophic Lateral SclerosisA phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbersStructure-activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis.Neurotrophic natural products: chemistry and biology.Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development.Therapeutic armamentarium for treating depression.Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside.Comparison of microbial and photochemical processes and their combination for degradation of 2-aminobenzothiazole.Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.Effect of riluzole on Ca2+ movement and cytotoxicity in Madin-Darby canine kidney cells.Interaction of high concentrations of riluzole with recombinant skeletal muscle sodium channels and adult-type nicotinic receptor channels.Agonist-induced periodic vasomotion in rat isolated pulmonary artery.High affinity interaction of mibefradil with voltage-gated calcium and sodium channels.Riluzole suppresses post-sigh, but not spontaneous apnoeas during sleep in rats.Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis.Respiratory-like rhythmic activity can be produced by an excitatory network of non-pacemaker neuron models.Do sodium channel blockers have neuroprotective effect after onset of ischemic insult?Biomarkers of Amyotrophic Lateral Sclerosis: Current Status and Interest of Oxysterols and Phytosterols.
P2860
Q24200270-C5BD1AA2-B21A-4FC7-A5F2-16DDBE831CFAQ24200377-E82B347F-BBD5-4280-9596-6C2F48B71467Q24234414-3CD47A5E-A388-4878-B930-B835D5BC8B18Q24234523-F235A732-7314-49E1-8F4F-3CD866B31DFAQ24241017-EA85C65D-59FE-4EA1-84AF-CA2BB124C096Q24241759-7153145C-DF2A-42FD-838A-49595DD3DE2FQ24533254-5DE300E3-12DC-4594-A793-AD69FFF7171EQ27015029-48F61BC6-47BE-4DC7-87D7-82EB63F39E78Q28748172-FF222126-7C4E-49A2-BA39-EE6553F21838Q33843060-AD5D9855-5CB0-4390-AA0D-49259D20AFD5Q34104378-3E6BF3F6-427F-4099-912F-227B734E0835Q34112946-F89A359D-90C5-488B-9CEA-E4148A8416B3Q34509446-62EF423B-1210-4509-90DD-377EBC742BE9Q34549829-B015DFC1-3CC1-418A-8E06-26D5C5799F3CQ35015986-C1532C7D-7269-4948-9278-5EABC6293038Q35015993-92DA2BC4-4206-4282-8C88-80C279DB624BQ36407877-4AC96A1E-4AC7-411D-AC6D-7761AD876D0FQ36799584-647E5D71-052C-45D2-9BB8-CF05BDB0ACCBQ37278447-42246EE7-D2E1-48B7-B9B4-E65CAB6E12E3Q37623342-BF7F54EC-DBE9-48DF-B49F-82F0B23F89C8Q37627169-DFB9DD6C-5679-418B-9F70-9D81C2D8EB84Q37777008-A0D90749-C6D1-4B54-91C2-4638DA7A3356Q38457735-D46B6950-33A3-41A4-AAF5-5145781B4476Q38607638-0B0909A0-37A7-45B8-9CF4-F80D9858A9F6Q38741121-AF2E7540-FB4C-404B-B182-425380CC2FFAQ40238809-E51C131D-F438-4340-A62A-96EEFE029E6FQ40699967-A25905D8-3534-4539-8037-230D9A28BDDDQ42477696-8C0242F8-E18A-46A9-BC0B-9A7F852F7F0CQ43167290-6C6B806F-4923-4EA7-BED2-782633746244Q43815287-F470AC0F-3B6D-4384-95B6-3C4F54816B9BQ44029872-C8B555BF-E605-45F5-A6B9-BF338310CD64Q47950775-7C9E126F-1B87-4A3A-8EA5-AD1ABA208A15Q48164686-73534F24-4865-43D5-8748-BFE94C019BCDQ49365640-3D353BC0-8805-4D6E-9128-CE208212989C
P2860
Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Riluzole. A review of its phar ...... amyotrophic lateral sclerosis.
@en
type
label
Riluzole. A review of its phar ...... amyotrophic lateral sclerosis.
@en
prefLabel
Riluzole. A review of its phar ...... amyotrophic lateral sclerosis.
@en
P2093
P1433
P1476
Riluzole. A review of its phar ...... amyotrophic lateral sclerosis.
@en
P2093
P304
P356
10.2165/00003495-199652040-00010
P577
1996-10-01T00:00:00Z
P6179
1052597560